C12Y 304/19012
Ubiquitinyl hydrolase 1
Official title: Ubiquitinyl hydrolase 1 (3.4.19.12)
C12Y304/19012 (Ubiquitinyl hydrolase 1) appears on 43 US grants and 90 published applications in this corpus.
Search patents in C12Y- Granted patents
- 43
- Published applications
- 90
- Assignees
- 50
- Inventors
- 137
- Latest grant
- 4 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1992 | 1 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 0 | 0 |
| 1998 | 0 | 0 |
| 1999 | 0 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 0 |
| 2003 | 0 | 0 |
| 2004 | 0 | 0 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 0 | 1 |
| 2011 | 0 | 1 |
| 2012 | 0 | 1 |
| 2013 | 2 | 3 |
| 2014 | 1 | 3 |
| 2015 | 0 | 5 |
| 2016 | 1 | 4 |
| 2017 | 5 | 6 |
| 2018 | 4 | 5 |
| 2019 | 4 | 4 |
| 2020 | 3 | 6 |
| 2021 | 1 | 5 |
| 2022 | 3 | 11 |
| 2023 | 7 | 10 |
| 2024 | 3 | 14 |
| 2025 | 4 | 4 |
| 2026 | 4 | 7 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- USP10 targeted self-deliverable siRNA compositions and methods for preventing or inhibiting fibrosis and/or scarring4 Aug 2026US 12,698,501 B2The Research Foundation for The State University of New York
- Compounds for treatment of osteoarthritis21 Apr 2026US 12,606,827 B2Altos Labs, Inc.
- Universal donor cells24 Feb 2026US 12,559,726 B2Crispr Therapeutics AG
- Compositions and methods for using engineered deubiquitinases for probing ubiquitin-dependent cellular processes24 Feb 2026US 12,559,739 B2The Trustees of Columbia University in the City of New York
- Compositions and methods for using engineered deubiquitinases for probing ubiquitin-dependent cellular processes8 Jul 2025US 12,351,844 B2The Trustees of Columbia University in the City of New York
- Compositions and methods for using engineered deubiquitinases for probing ubiquitin-dependent cellular processes13 Aug 2026US 2026/0234594 A1The Trustees of Columbia University in the City of New York
- Modified cell and use thereof23 Jul 2026US 2026/0209698 A1
- Drug containing active sulfur compound as its main component25 Jun 2026US 2026/0174827 A1Bio-Xcelerator, Inc.
- Methods of treating cancers14 May 2026US 2026/0130910 A1
- Modified mammalian cells9 Apr 2026US 2026/0098254 A1Genentech, Inc.
Most cited
By later US patents
- Methods of generating desired amino-terminal residues in proteins51US 5,093,242 AMassachusetts Institute of Technology · 1992
- Neural proteins as biomarkers for nervous system injury and other neural disorders38US 8,492,107 B2Banyan Biomarkers, Inc. · 2013
- Neural proteins as biomarkers for nervous system injury and other neural disorders9US 9,810,698 B2Banyan Biomarkers, Inc. · 2017
- Antisense oligonucleotide directed removal of proteolytic cleavage sites from proteins7US 10,364,432 B2Academisch Ziekenhuis Leiden (H.O.D.N. Lumc) · 2019
- Universal donor cells6US 11,566,230 B2Crispr Therapeutics AG · 2023